John P. Hamill - 27 Mar 2025 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
SrVP/CFO/Prin Fin & Acct Ofcr
Signature
/s/ John Hamill
Issuer symbol
APRE
Transactions as of
27 Mar 2025
Net transactions value
$0
Form type
4
Filing time
31 Mar 2025, 16:31:29 UTC
Previous filing
16 Oct 2024
Next filing
11 Dec 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Award $0 +3,365 +17% $0.000000 22,733 27 Mar 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APRE Stock Options (Right to Buy) Award $0 +13,460 $0.000000 13,460 27 Mar 2025 Common Stock 13,460 $2.20 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 27, 2026, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F2 Twenty-five percent of these options vest on March 27, 2026, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.